CLBT
Cellebrite DI Ltd
$11.08
▼ 0.5%Updated Oct 2, 3:37 PM ET
CLBT at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
11.0%
Interest Coverage
—
Current Ratio
1.56x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
Cellebrite DI Ltd (CLBT) is a small-cap company in the Technology industry, part of the Information Technology sector of the S&P 500.
In its latest reported year it generated about $475.68M in revenue and $78.33M in net profit.
Our model rates CLBT Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (7 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
84.1% average over the last 3 years
±1.8 pts around 82.3% across 7 years
grew in 6 of the last 6 year-over-year periods
positive in 7 of 7 years
11.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
4Y CAGR
17.9%
Revenue moved from $171.85M in 2019 to $475.68M in 2025, a 18.5% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
84.2%
Operating Margin
14.0%
Net Margin
16.5%
ROE
—
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
—
Leverage: debt-to-equity is n/a, with a current ratio of 1.6x. Detailed balance-sheet leverage is limited for this name.
Operating CF
$173.54M
Free Cash Flow
$160.32M
FCF Margin
33.7%
In the latest year Cellebrite DI Ltd produced about $173.54M of operating cash flow and $160.32M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
Coverage is weak, the payout was cut recently, or it's being financed rather than earned — treat the current yield as fragile.
Total paid (latest FY)
$100.00M
History on record
3 years
dividend uses 62% of free cash flow
128% of net income paid out
total dividends increased 1 year in a row
payout was cut at least once in the last 3 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
CLBT trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$11.03
Current price
$11.08
Starting FCF (latest 10-K)
$160.32M
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where CLBT sits versus its Information Technology sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 98 Information Technology companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How CLBT stacks up against its Information Technology peers — valuation, profitability, and growth versus the sector median.
In the Information Technology sector (230 S&P 500 companies), CLBT ranks #133 of 230 by our overall rating.
P/E vs sector
—
median 39.3x
ROE vs sector
—
median 17.5%
Growth vs sector
—
median 17.7%
Sector rank
#133
of 230 by rating
Peers are the closest Information Technology companies by sub-industry and size. Sector median is across all 230 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $11.08 today · expected CAGR -13% – -4%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $513.73M | $554.83M | $599.21M | $647.15M | $698.92M |
| Net income | $82.20M | $88.77M | $95.87M | $103.54M | $111.83M |
| EPS | $0.33 | $0.36 | $0.38 | $0.42 | $0.45 |
| Share price (low) | $3.95 | $4.27 | $4.61 | $4.98 | $5.38 |
| Share price (high) | $6.59 | $7.12 | $7.69 | $8.30 | $8.97 |
| CAGR (low–high) | -64% / -41% | -38% / -20% | -25% / -11% | -18% / -7% | -13% / -4% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for CLBT:
- As an established S&P 500 member in Information Technology, it brings scale and a long operating history.
The case against CLBT:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Cellebrite DI Ltd is a small-cap information technology business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 15 Wall Street analysts covering CLBT recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
CLBT's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
CLBT — frequently asked questions
Is CLBT a good stock to buy?
We don't give buy or sell advice. Review Cellebrite DI Ltd's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does CLBT's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Cellebrite DI Ltd's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for CLBT calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this CLBT analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell CLBT. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.